Abbott Laboratories
ABT · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $234 | $237 | $232 | $196 |
| - Cash | $8 | $7 | $7 | $8 |
| + Debt | $13 | $13 | $13 | $15 |
| Enterprise Value | $240 | $243 | $238 | $204 |
| Revenue | $11 | $11 | $10 | $11 |
| % Growth | 2% | 7.6% | -5.6% | – |
| Gross Profit | $6 | $6 | $5 | $6 |
| % Margin | 55.7% | 56.4% | 52.6% | 51% |
| EBITDA | $3 | $3 | $3 | $3 |
| % Margin | 26.5% | 27.4% | 25.8% | 27.2% |
| Net Income | $2 | $2 | $1 | $9 |
| % Margin | 14.5% | 16% | 12.8% | 84.1% |
| EPS Diluted | 0.94 | 1.01 | 0.758 | 5.27 |
| % Growth | -6.9% | 33.2% | -85.6% | – |
| Operating Cash Flow | $3 | $2 | $1 | $3 |
| Capital Expenditures | -$0 | -$1 | -$0 | -$1 |
| Free Cash Flow | $2 | $2 | $1 | $2 |